Immunic, Inc. (NASDAQ:IMUX – Get Free Report) saw a large decrease in short interest during the month of April. As of April 30th, there was short interest totaling 1,336,756 shares, a decrease of 83.9% from the April 15th total of 8,327,660 shares. Based on an average trading volume of 417,520 shares, the short-interest ratio is presently 3.2 days. Currently, 11.4% of the shares of the stock are short sold.
Institutional Investors Weigh In On Immunic
Several institutional investors and hedge funds have recently made changes to their positions in IMUX. Nantahala Capital Management LLC bought a new stake in Immunic in the fourth quarter worth approximately $2,337,000. Vanguard Group Inc. grew its position in shares of Immunic by 5.3% during the 3rd quarter. Vanguard Group Inc. now owns 4,345,105 shares of the company’s stock worth $3,832,000 after buying an additional 219,957 shares during the period. Laurion Capital Management LP increased its stake in shares of Immunic by 106.3% in the 4th quarter. Laurion Capital Management LP now owns 3,882,162 shares of the company’s stock valued at $2,072,000 after acquiring an additional 2,000,000 shares in the last quarter. Millennium Management LLC lifted its position in shares of Immunic by 544.6% during the 4th quarter. Millennium Management LLC now owns 3,419,299 shares of the company’s stock valued at $1,825,000 after acquiring an additional 2,888,829 shares during the period. Finally, Focus Partners Wealth boosted its stake in Immunic by 1.5% during the third quarter. Focus Partners Wealth now owns 2,581,587 shares of the company’s stock worth $2,276,000 after acquiring an additional 39,063 shares in the last quarter. Institutional investors own 51.82% of the company’s stock.
Wall Street Analyst Weigh In
IMUX has been the subject of a number of recent research reports. HC Wainwright reaffirmed a “buy” rating and issued a $22.00 target price (up from $5.00) on shares of Immunic in a report on Thursday, April 30th. Stifel Nicolaus set a $25.00 price target on Immunic and gave the stock a “buy” rating in a report on Thursday, April 16th. Wall Street Zen lowered shares of Immunic from a “hold” rating to a “sell” rating in a report on Sunday, April 19th. Lifesci Capital raised shares of Immunic to a “strong-buy” rating in a report on Monday, May 4th. Finally, Guggenheim began coverage on shares of Immunic in a research note on Tuesday, March 24th. They set a “buy” rating and a $70.00 price target for the company. Three investment analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Immunic has a consensus rating of “Buy” and an average price target of $52.43.
Immunic Trading Down 0.8%
NASDAQ:IMUX traded down $0.09 on Tuesday, reaching $11.91. 97,002 shares of the stock traded hands, compared to its average volume of 338,041. Immunic has a 1-year low of $5.06 and a 1-year high of $15.10. The company’s 50 day moving average is $11.31 and its 200-day moving average is $8.52. The firm has a market capitalization of $162.19 million, a price-to-earnings ratio of -1.69 and a beta of 1.20.
Immunic (NASDAQ:IMUX – Get Free Report) last posted its quarterly earnings data on Thursday, February 26th. The company reported ($1.20) EPS for the quarter, missing analysts’ consensus estimates of ($1.02) by ($0.18). On average, equities research analysts forecast that Immunic will post -3.44 EPS for the current fiscal year.
About Immunic
Immunic, Inc is a clinical-stage biopharmaceutical company focused on developing novel oral therapies to treat chronic inflammatory and autoimmune diseases as well as certain cancers. The company’s research strategy centers on small-molecule immunology, aiming to offer targeted treatments with improved safety and tolerability profiles. By modulating key signaling pathways within the immune system, Immunic seeks to address underlying disease mechanisms and achieve durable therapeutic benefits for patients.
Immunic’s lead product candidate, vidofludimus calcium (IMU-838), is an oral selective dihydroorotate dehydrogenase (DHODH) inhibitor in Phase 2 clinical development for conditions including ulcerative colitis, Crohn’s disease and relapsing multiple sclerosis.
Read More
- Five stocks we like better than Immunic
- Navy Catalyst Ignites Odysight’s Growth Engine
- AST SpaceMobile Plummets on Galactic Q1 Miss: Can Vertical Integration Save the SpaceX Rival?
- Axon Surged After Earnings and Is Still Down Over 50% From Highs
- The Event That Could Redefine Apple’s Summer Rally
Receive News & Ratings for Immunic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immunic and related companies with MarketBeat.com's FREE daily email newsletter.
